TABLE 3.
Viral kinetics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2
| Sample type | Time of illness | SARS‐CoV | MERS‐CoV | SARS‐CoV‐2 | |
|---|---|---|---|---|---|
| URT | Week 1 | 32%, 5.36① 43 ; 58%, 4.18① 44 ; 39%② 44 | 75.5%, 4.5③ 51 ; 25%, 5③ 45 ; 33.3%, 5⑤ 45 | 5.3③ 52 ; 31.5 CT⑤ 110 ; 36 CT③ 110 50%, 32.1 CT③ 23 ; 100%, 30.5 CT⑤ 112 | |
| Week 2 | 68%, 7.28① 43 ; 60%, 5.25① 44 ; 32%② 44 ; 42.3%, 5.8① 49 | 45.8%, 3.5③ 51 ; 88.2%, 5.5③ 45 ; 23.5%, 4.5⑤ 45 | 3.8③ 52 ; 37 CT⑤ 110 ; 38 CT③ 110 ; 25%, 31.65 CT③ 23 ; 94.4%, 31.95 CT⑤ 112 | ||
| Week 3 | 4.99① 43 ; 39%, 4.77① 44 ; 25%② 44 | 0③ 51 ; 27.3%, 4.5③ 45 ; 5.88%, 5.5⑤ 45 | 40 CT⑤ 110 ; 38 CT③ 110 ; 69.2%, 33.05 CT⑤ 112 | ||
| LRT | Week 1 | 100% 44 | 100%, 8 51 ; 100%, 6④ 45 | 6.1⑥ 52 | |
| Week 2 | 100% 44 | 93%, 7 51 ; 100%, 6.8④ 45 | 5.8⑥ 52 | ||
| Week 3 | 67% 44 | 66.7%, 5 51 ; 100%, 6.3④ 45 | N/A | ||
| Stool | Week 1 | 47%, 6.52 44 | 16.7%, 4.5 51 | 25%, 31.65 CT③ 23 ; 75%, 28.2 CT 112 | 53%, 2.74‐5.08 52 |
| Week 2 | 97% 43 ; 70%, 7.95 44 ; 87.2%, 7.0 49 | 14.3%, 4 51 | 37.5%, 26.5 CT③ 23 ; 42.9%, 30.3 CT 112 | ||
| Week 3 | 54%, 5.33 44 | 0 51 | N/A | ||
| Blood | Week 1 | 33% 44 ; 50%, 2.37 53 | 48.1%, 4 51 ; 10%, 4.8 45 | 0 112 | 40% 23 |
| Week 2 | 25% 44 ; 50%, 2.59 53 41.5%, 2.7 49 | 25%, 3 51 ; 29.4%, 4.2 45 | 25%, 33.15 CT 112 | ||
| Week 3 | 33% 44 ; 25%, 2.18 53 | 0 51 ; 17.6%, 4.7 45 | N/A | ||
| Urine | Week 1 | 33% 44 | 9%, 2 51 | 0 112 ; 6.9% 24 | |
| Week 2 | 25% 44 28.8%, 4.4 49 | 0 51 | |||
| Week 3 | 14% 44 | 0 51 | |||
Note: Data are expressed as “positive rate, viral load (log10 copies/mL or CT value),” which are converted directly from raw data or estimated from figures. Respiratory sample type:①NP aspirates, ②Other URT specimens consisted of throat and nasal swabs, throat swabs, nasopharyngeal swabs, and nasal swabs, ③throat swabs, ④sputum or tracheal aspirate, ⑤nasopharyngeal swabs, ⑥Sputum. Time indicated in References 51 and 23 is the time of diagnosis, NOT the time of illness.